Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas
Revista ft · 19.05.2026 · 30 (158) · 01-14
DOI: 10.69849/t91t7306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 19.05.2026. Verfasst von Ana Beatriz Spreafico Montes Pereira und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Obesity and type 2 diabetes mellitus (T2DM) are major global public health problems, strongly associated with increased cardiovascular and metabolic risk as well as reduced quality of life. These conditions frequently coexist and share pathophysiological mechanisms related to insulin resistance, low-grade chronic inflammation, and metabolic dysfunction. In this context, new pharmacological therapies have been developed to improve glycemic control and promote weight loss, highlighting intestinal hormone receptor agonists such as tirzepatide and retatrutide.
Objectives
To compare the efficacy of retatrutide and tirzepatide in the management of obesity and type 2 diabetes mellitus. As specific objectives, this study aims to analyze the mechanisms of action of both drugs, evaluate their clinical effects on weight loss and glycemic control, and discuss their future therapeutic perspectives in clinical practice. Methodology: This is an integrative literature review aimed at gathering and analyzing recent scientific evidence on the comparison between retatrutide and tirzepatide in the treatment of obesity and T2DM. The search was conducted in PubMed and SciELO databases using MeSH and DeCS descriptors combined with Boolean operators, such as “retatrutide AND tirzepatide AND obesity AND type 2 diabetes mellitus.” Articles published between 2020 and 2026, available in full text in Portuguese and English, addressing the proposed topic, were included. Results and discussion: The analyzed studies indicate that both tirzepatide and retatrutide demonstrate significant efficacy in reducing body weight and improving glycemic control in patients with obesity and T2DM. Tirzepatide, a dual agonist of GIP and GLP-1 receptors, shows significant improvement in insulin sensitivity, reduction in glycated hemoglobin, and substantial weight loss. Retatrutide, considered a triple agonist therapy (GLP-1, GIP, and glucagon), has shown even greater potential in body weight reduction, as well as promising metabolic effects. Early evidence suggests that both therapies may represent significant advances in the treatment of obesity and T2DM, although long-term studies are still needed to assess safety and cardiovascular outcomes.
Conclusion
It is concluded that retatrutide and tirzepatide represent important innovations in the treatment of obesity and type 2 diabetes mellitus, with promising results in weight loss and metabolic control. Retatrutide may demonstrate superior potential in some outcomes; however, both therapies still require further clinical investigation to consolidate their role in medical practice.
Zitieren
APA
Pereira, A. B. S. M., Ferreira, B. D. A., Taborga, K. M., Mendonça, P. H. P., Carneiro, P. L. G., & Tourinho, L. D. O. S. (2026). Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas. Revista ft, 30(158), 01-14. https://doi.org/10.69849/t91t7306
Vancouver
Pereira ABSM, Ferreira BDA, Taborga KM, Mendonça PHP, Carneiro PLG, Tourinho LDOS. Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas. Revista ft. 2026;30(158):01-14. doi:10.69849/t91t7306
BibTeX
@article{Pereira2026,
author = {Pereira, Ana Beatriz Spreafico Montes and Ferreira, Brenda de Almeida and Taborga, Kamila Martins and Mendonça, Pedro Henrique Passos and Carneiro, Pedro Lucas Góis and Tourinho, Luciano de Oliveira Souza},
title = {Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {158},
pages = {01--14},
doi = {10.69849/t91t7306}
}
EUVIMED